

# A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06055959

---

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	UCB Biopharma SRL
Enrollment	8 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- United States of America (USA) specific inclusion criterion:
- \- Participant must be 12 to \<18 years of age at the time of signing the Informed consent/assent according to local regulation
- Rest of world (ROW) specific inclusion criterion:
- \- Participant must be 2 to \<18 years of age at the time of signing the Informed consent/assent according to local regulation
- Participant has a diagnosis of generalized myasthenia gravis (gMG) confirmed by a prior positive serologic test result to acetylcholine receptor (AChR) prior to Screening
- ... and 5 more (see full listing online)

### Exclusion (5)

- Participant has known positive serology for muscle-specific kinase
- Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study
- Participant has had a thymectomy within 6 months prior to Baseline
- Participant has minimal Manifestation Status of MG based on the clinical judgement of the Investigator
- Current or recent systemic infection within 2 weeks prior to Baseline or infection requiring intravenous antibiotics within 4 weeks prior to Baseline

## Locations (9 total)

---

Mg0014 50168, Chicago, Illinois, United States  
Mg0014 50574, Flower Mound, Texas, United States  
Mg0014 40144, Milan, Italy  
... and 6 more locations